Cell line/type | GSC (glioma stem-like cells) |
---|---|
Species | Human |
Animal free | Yes |
Product | DMEM-F12 Balvers et al. 2015 |
Balvers, R. K., Lamfers, M. L., Kloezeman, J. J., Kleijn, A., Pont, L. M. B., Dirven, C. M., & Leenstra, S. (2015). ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. Journal of translational medicine, 13(1), 74. This study investigated the therapeutic benefit of combination therapy in patient-derived glioma stem-like cells (GSC). Combination therapy feasibility was tested on established GBM cell lines U373 and T98. An in vitro drug-screening assay was developed, based on GSC cultures derived from a panel of primary patient tissue samples to evaluate the effect of PARPi (ABT-888) monotherapy and combination therapy with TMZ. The cells were cultured in serum-free DMEM-F12, supplemented with different components as specified in the Methods, under the heading; Cell cultures. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359449/pdf/12967_2015_Article_427.pdf |
|
Source | Literature - own formulation |
Chemically defined > Yes | Yes |
Antibiotics free > No | No |
Contains phenol red > Yes | Yes |